contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


correction-last-trading-day-before-reverse-share-split

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Q-Linea operates in the medical technology sector. The company specializes in research and development of instruments and consumables. The products are mainly used in the treatment of infectious diseases and blood poisoning, and include diagnostic and analytical tools, as well as basic sample handling. The technology is based on the so-called ID and AST technology. Q-Linea was founded in 2008 and is headquartered in Uppsala.

Q-Linea

Q-linea AB (publ) (the “Company”) issues a correction to the press release regarding the timetable for the reverse share split, published on 8 July 2025. The correction concerns the fact that...

<div class="mfn-preamble"><p><strong>Q-linea AB (publ) (the “Company”) issues a correction to the press release regarding the timetable for the reverse share split, published on 8 July 2025. The correction concerns the fact that the press release incorrectly stated 13 July 2025 as the last trading day before the reverse share split. The correct last trading day is 11 July 2025. All other information in the press release on 8 July 2025 remains unchanged.</strong></p></div><div class="mfn-body"><p>The record date for the reverse share split is 15 July 2025. The last day of trading in the Company's shares before the reverse share split is 11 July 2025 and the first day of trading in the Company's shares after the reverse share split is 14 July 2025. The Company's share price will thus reflect the effect of the reverse share split as of 14 July 2025. The reverse share split will take place automatically via Euroclear Sweden AB and shareholders do not need to take any action.</p><p>Through the reverse share split, the total number of shares in the Company will decrease from 6,436,873,000 to 6,436,873.</p><p>As a result of the reverse share split, the Company's share will change its ISIN code as of 14 July 2025. The new ISIN code for the Company's share is SE0025420714.</p><p>The shareholders of the Company will automatically receive a new, lower, number of shares in proportion to the holding on the record date. Shareholders whose holdings of shares on the record date are not evenly divisible by one thousand (1000) will receive shares free of charge in order for the holding to be evenly divisible by one thousand (1000). Provision of shares is made by Euroclear Sweden AB, without the need for further measures to be taken by shareholders.</p></div><div class="mfn-footer mfn-contacts mfn-828219978778"><p><strong class="mfn-heading-1">For more information, please contact:</strong></p><hr><p>Stuart Gander, President &amp; CEO, Q-linea <br><a rel="noopener" href="mailto:stuart.gander@qlinea.com">Stuart.Gander@qlinea.com</a><br>+1 857 409 7463</p><p>Christer Samuelsson, CFO /IR, Q-linea AB<br><a rel="noopener" href="mailto:Christer.Samuelsson@qlinea.com">Christer.Samuelsson@qlinea.com</a><br>+46 (0) 70-600 15 20<br></p></div><div class="mfn-footer mfn-about mfn-2048cb62925b"><p><strong class="mfn-heading-1">About Q-linea</strong></p><hr><p>Q-linea’s rapid AST system, ASTar®, accelerates and simplifies the time-sensitive workflows faced during the treatment of patients with bloodstream infections and sepsis. Hospitals use ASTar to vastly reduce the time to optimal antimicrobial therapies and ensure that patients receive the correct treatments sooner — when time matters most. We are helping to create sustainable healthcare, now and in the future, and safeguard the effectiveness of antibiotics for generations to come.<br>Q-linea is headquartered in Uppsala, Sweden and has regional offices in Italy and the USA, with partnerships worldwide.<br>ASTar Instrument and ASTar BC G- Consumable kit are CE-IVD marked and FDA 510(k) cleared. For more information, please visit www.qlinea.com</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/60f6cdef-79d9-452f-a1b9-f7d8e7c7b57a/correction-last-trading-day-before-reverse-share-split.pdf" class="mfn-generated mfn-primary">Correction: Last trading day before reverse share split</a></p></div>